Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Shuttle Pharma is a Delaware-incorporated discovery and development stage pharmaceutical company that has historically focused on radiation therapy–related oncology and now also owns the Molecule.ai AI platform for molecular discovery and early-stage drug development.
Through its Forms 8-K, Shuttle Pharma reports material events such as asset purchase agreements, private placements, consulting arrangements and changes to clinical programs. For example, 8-K filings describe the binding term sheet and subsequent asset purchase agreement under which a wholly owned subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Other 8-Ks detail a securities purchase agreement for a pre-funded warrant, settlement and winddown of Ropidoxuridine clinical trials, and communications related to Nasdaq listing requirements.
Shuttle Pharma’s registration statements on Form S-1 and S-1/A offer a broader business overview, including its origins as a radiation therapy–focused specialty pharmaceutical company, the development history of Ropidoxuridine, and a detailed description of the Molecule.ai platform’s architecture and functions. These filings also explain the terms of registered resales of shares issuable upon exercise of the pre-funded warrant and provide risk factor discussions relevant to a development-stage biotech and AI platform owner.
On Stock Titan, users can review these filings as they are made available from EDGAR and use AI-powered summaries to quickly understand key points such as transaction structures, milestone-based consideration, changes in clinical strategy, and implications of listing compliance notices. Access to Form 4 insider transaction reports, when filed, and periodic reports like Forms 10-K and 10-Q, when available, helps investors track governance, capital structure and ongoing operations.
By consolidating Shuttle Pharma’s SEC filings and layering AI-generated explanations on top of the raw documents, this page is designed to make it easier to follow SHPH’s evolution as a company combining oncology development with AI-enabled molecular research infrastructure.
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of approximately $11.7 million for the year ended December 31, 2025, with no revenue and a working capital deficit of about $7.5 million, raising substantial doubt about its ability to continue as a going concern.
During 2025 the company shifted strategy by acquiring substantially all assets of Molecule.ai, an AI-driven platform for molecular discovery, for total consideration of about $10.1 million, while committing to wind down clinical trials of its lead drug candidate, Ropidoxuridine. Research and development spending rose to $4.1 million, largely tied to clinical trial and wind-down costs, and general and administrative expenses increased to $5.7 million, driven in part by $3.5 million of investor-relations advertising.
Shuttle faced repeated Nasdaq listing deficiencies, executing a 1-for-25 reverse stock split in June 2025 and conducting multiple financings, including a March 2026 underwritten offering that raised gross proceeds of $3.5 million. Stockholders’ equity was $2,254,446 at year-end 2025, below Nasdaq’s $2.5 million requirement, though management believes subsequent capital raises restored compliance.
Shuttle Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement and priced a public offering of 2,238,800 common shares and pre-funded warrants to purchase 4,761,200 common shares for aggregate gross proceeds of about $3.5 million, before fees and expenses. The offering, placed on a reasonable best-efforts basis by E.F. Hutton & Co., closed on March 9, 2026. Pre-funded warrants are immediately exercisable at $0.001 per share, subject to a 4.99% (or 9.99% by election) Beneficial Ownership Limitation. The company plans to use up to $1.5 million of net proceeds for future marketing efforts and the remainder for working capital and general corporate purposes, with 30-day lock-ups for the company and its executives and directors.
Shuttle Pharmaceuticals Holdings, Inc. is offering 2,238,800 shares of common stock and pre-funded warrants to purchase up to 4,761,200 shares of common stock at $0.50 per share and $0.499 per pre-funded warrant, respectively.
The pre-funded warrants are immediately exercisable for $0.001 per share and will not be listed. The offering is being placed on a "best efforts" basis by E.F. Hutton & Co., with expected delivery on or about March 9, 2026. Net proceeds are estimated at approximately $3.04 million, of which up to $1.5 million is intended for marketing and the remainder for working capital and general corporate purposes.
The company completed an asset acquisition of Molecule.ai on November 20, 2025 and committed to discontinue its clinical trials of Ropidoxuridine on November 20, 2025. Preliminary unaudited 2025 results show an expected net loss between $(10.9) million and $(12.1) million; cash and current assets and certain liabilities are presented with working capital deficit expectations as of December 31, 2025.
Shuttle Pharmaceuticals Holdings, Inc. furnished preliminary, unaudited results for the year ended December 31, 2025, showing no revenue and an estimated net loss between $10.9 million and $12.1 million, compared with an actual net loss of $9.1 million in 2024.
Total operating expenses for 2025 are expected between $10.7 million and $11.9 million, up from $7.7 million, driven mainly by a jump in general and administrative costs to an estimated $5.2 million–$5.8 million versus $1.4 million in 2024, largely due to $3.6 million of investor relations advertising.
Research and development spending is projected in a narrow range around the prior year’s $3.6 million, while legal and professional expenses are expected to decline slightly from $2.7 million. As of December 31, 2025, the company anticipates current assets of about $0.5 million and current liabilities of $1.2 million–$1.3 million, implying a working capital deficit of $0.7 million–$0.8 million, compared with positive working capital of $0.7 million a year earlier.
Shuttle Pharmaceuticals Holdings, Inc. is registering up to 2,229,300 shares of common stock and pre-funded warrants to purchase up to 2,229,300 shares in a best efforts public offering. The assumed public offering price is $1.57 per share or pre-funded warrant, implying up to $3.5 million in gross proceeds and estimated net proceeds of about $3.03 million if fully sold.
The company plans to use up to $1.5 million for future marketing, including a new agreement with IR Agency LLC, and the balance for working capital and general corporate purposes. Shuttle recently acquired the AI-driven Molecule.ai platform and discontinued clinical trials of its lead drug candidate, and it preliminarily estimates a 2025 net loss between $10.9 million and $12.1 million with no revenue.
Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 to offer up to 2,229,300 shares of common stock, or pre-funded warrants in lieu of shares, plus the common shares underlying those pre-funded warrants. The assumed price is $1.57 per share, matching the February 5, 2026 Nasdaq close.
The company recently acquired the Molecule.ai AI drug-discovery platform and has discontinued clinical trials of its lead drug candidate, Ropidoxuridine, signaling a shift toward AI-driven discovery. Preliminary 2025 results show no revenue and a higher net loss of $10.9–$12.1 million versus $9.1 million in 2024, driven largely by a jump in general and administrative expenses tied to $3.6 million of investor-relations advertising.
As of December 31, 2025, Shuttle expects a working capital deficit of $0.7–$0.8 million and $9.8 million of intangible assets from the Molecule.ai acquisition, with $6.4 million of contingent and payable consideration remaining. Net proceeds from this offering are estimated at about $3.03 million, with $1.5 million earmarked for marketing and the balance for working capital and general corporate purposes.
Shuttle Pharmaceuticals Holdings, Inc. amended its consulting agreement with Number 2 Capital Corp., the entity owned by interim co-Chief Executive Officer Christopher Cooper. The amendment, dated January 29, 2026, extends the agreement’s term to August 1, 2026, effective September 11, 2025.
Under the agreement, the consultant is paid $20,000 per month, is expected to work 40 hours per week, and is subject to standard confidentiality and non-disclosure provisions. Either party may terminate the agreement on 30 days’ notice, or immediately for cause.
Shuttle Pharmaceuticals Holdings, Inc. has filed a resale prospectus covering 625,156 shares of common stock issuable upon exercise of a pre-funded warrant held by a single selling stockholder. The warrant has a nominal exercise price of $0.001 per share and no expiration, with a 4.99% beneficial ownership cap.
The warrant was issued in a November 2025 private placement that generated approximately $2.5 million in gross proceeds for Shuttle; the company will receive no proceeds from the resale of these registered shares. A prior June 2025 private placement with the same investor raised about $4.3 million.
Shuttle is pivoting its business by acquiring substantially all assets and liabilities of Molecule.ai, an AI-driven molecular discovery platform, while discontinuing clinical trials of its lead candidate Ropidoxuridine. Incorporated financial statements include an auditor paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Shuttle Pharmaceuticals Holdings, Inc. reported leadership changes. The Board appointed Yuying Liang, CPA as Chief Financial Officer, effective from an engagement under which her firm, Yuying Liang Professional Corp., will provide bookkeeping, accounting, and financial reporting services for a monthly fee of $15,000 plus applicable taxes. Former CFO Chris Cooper will no longer serve as Chief Financial Officer but will continue in his role as Interim Chief Executive Officer.
The company also disclosed that Sachin Pathigoda resigned from the Board of Directors, effective immediately, and stated his resignation was not due to any disagreement with the company’s operations, policies, or practices. The Board has begun a process to identify a new director to fill the vacancy in line with the company’s bylaws and applicable law.